|
1.Landscape of Helper and Regulatory Antitumour CD4+ T cells in Melanoma
Oliveira et al., Nature (2022) – PMID: 35508657
Products used: PepMix CEF Pool , Human (MAGE-A1), Human (MAGE-A3), Human (MAGE-A4), Human (MAGE-A9), Human (MAGE-C), Human (MAGE-D), Human (MLANA), Human (PMEL), TYR, DCT, PRAME, NYESO-1
2.Local Delivery of low-dose anti–CTLA-4 to the Melanoma Lymphatic Basin leads to systemic Treg Reduction and Effector T cell Activation
Van Pul et al., Science Immunology (2022) – PMID: 35857579
Product used: PepMix Human (NY-ESO-1), Human (MAGEA4), and CEFT pool
3.Functional T Cell Reactivity to Melanocyte Antigens is lost during the Progression of Malignant Melanoma, but Is restored by Immunization
Przybyla et al., Cancers (Basel) (2021) – PMID: 33435427
Product used: PepMix Human (Melanocyte protein Pmel 17 gp100), Human (NY-ESO-1), Human (Tyrosinase), Human (MAGEA3), and Human (Melan-A/MART-1)
4.Identification of Novel HLA-Restricted Preferentially Expressed Antigen in Melanoma Peptides to Facilitate Off-The-Shelf Tumor-Associated Antigen-Specific T-Cell Therapies
Stanojevic et al., Cytotherapy (2021) – PMID: 33832817
Product used: PepMix Human (Prame/OIP4), and Human (Actin)
5.Sulfated Lactosyl Archaeol Archaeosomes Synergize with Poly(I:C) to Enhance the Immunogenicity and Efficacy of a Synthetic Long Peptide-Based Vaccine in a Melanoma Tumor Model
Akache et al., Pharmaceutics (2021) – PMID: 33673382
Product used: Custom services
6.Neoantigens in Cancer Immunotherapy – Review
Schumacher & Schreiber, Science (2015) – PMID: 25838375
7.An immunogenic personal Neoantigen Vaccine for Patients with Melanoma – Letter
Ott et al., Nature (2017) – PMID: 28678778
|
